Opioid-Oligomer Conjugates for Controlled CNS Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid agonist and analgesic combinations, while effective for pain relief, still pose challenges in minimizing opioid side effects and abuse potential due to rapid entry into the central nervous system and peripheral side effects such as constipation.
Innovation Solution
Development of compositions comprising opioid agonist compounds linked with a physiologically stable linker and a water-soluble oligomer, which slow the entry of opioids into the central nervous system and reduce peripheral side effects by forming a stable linkage that is hydrolytically or enzymatically degradable, allowing for controlled release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid agonist compounds are administered to achieve effective pain relief, then analgesic effect is improved, but abuse potential and CNS side effects increase due to rapid entry into the central nervous system
Solution Approach 1:
The patent uses a water-soluble oligomer as an intermediary carrier that temporarily binds to the opioid agonist compound. This oligomer acts as a mediator that controls the release rate of the opioid, allowing it to reach the target tissue slowly rather than entering the CNS rapidly. The oligomer-f opioid conjugate serves as an intermediate form that modulates the pharmacokinetics of the opioid compound.
Solution Approach 2:
The patent extracts the opioid agonist compound from its free form and attaches it to a water-soluble oligomer. This separation of the opioid from its immediate active state reduces its ability to rapidly cross into the CNS while maintaining its eventual therapeutic effect. The oligomer portion is removed or degraded over time, releasing the opioid in a controlled manner.
2Reliability
If opioid agonist compounds are administered to achieve effective pain relief, then analgesic effect is improved, but peripheral side effects such as constipation increase
Solution Approach 1:
The patent applies local quality by creating a non-uniform distribution of opioid concentration over time and space. The oligomer-f opioid conjugate provides localized, controlled release of the opioid at the site of administration, creating a gradient that favors therapeutic effect at the target while minimizing exposure in peripheral tissues that cause side effects like constipation.
3Reliability
If high doses of opioids are administered to ensure adequate pain relief, then analgesic effect is improved, but abuse potential and side effects increase
Solution Approach 1:
The patent implements periodic action through the controlled, time-dependent release of the opioid from the oligomer conjugate. Instead of a single high-dose administration, the system provides sustained, lower-dose release over an extended period. This periodic delivery maintains therapeutic levels while avoiding the peak concentrations that lead to abuse and side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions provide a synergistic analgesic effect while reducing the risk of opioid abuse and side effects by slowing opioid entry into the CNS and altering tissue distribution, thereby improving the therapeutic window and suitability for chronic use.
Implementation Method 1
certain opioid agonist compounds have been prepared and are believed to reduce the rate of opioid entry into the central nervous system
Implementation Method 2
forming a stable linkage that is hydrolytically or enzymatically degradable, allowing for controlled release
Implementation Method 3
forming a stable linkage that is hydrolytically or enzymatically degradable, allowing for controlled release
Data Source
AI summary
The present invention relates generally to the co-administration of an opioid agonist compound and an analgesic compound. In addition, the invention relates to, among other things, dosage forms for co-administration of an opioid agonist compound and an analgesic compound, methods for administering an opioid agonist compound and an analgesic compound, compositions comprising an opioid agonist compound and an analgesic compound, dosage forms comprising an opioid agonist compound and an analgesic compound, and so on.